Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 12, 2012, Pages 2958-2967

  Babick, Andrea ^a   Chapman, Donald ^a   Zieroth, Shelley ^b   Elimban, Vijayan ^a   Dhalla, Naranjan S ^a  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiac dysfunction; Cardiac gene expression; Plasma catecholamines; Renin angiotensin blockade; Subcellular remodelling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BMYO PROTEIN, RAT; CALCIUM BINDING PROTEIN; CATECHOLAMINE; LOSARTAN; MESSENGER RNA; MYOSIN HEAVY CHAIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; CARDIOMEGALY; CORONARY BLOOD VESSEL; DRUG EFFECT; GENETICS; HEART FAILURE; HEART FUNCTION TEST; HEART INFARCTION; HEART VENTRICLE REMODELING; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CATECHOLAMINES; CORONARY VESSELS; HEART FAILURE; HEART FUNCTION TESTS; LOSARTAN; MYOCARDIAL INFARCTION; MYOSIN HEAVY CHAINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR REMODELING;

RATTUS;

EID: 84871072961     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01623.x     Document Type: Article

References (51)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000; 35: 569-82.
2. Fedak PWM, Verma S, Weisel RD, et al. Cardiac remodeling and failure from molecules to man (Part I). Cardiovasc Physiol. 2005; 12: 1-11.
3. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999; 79: 215-62.
4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990; 81: 1161-72.
5. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 1998; 37: 279-89.
6. Dhalla NS, Rangi S, Babick AP, et al. Cardiac remodeling and subcellular defects in heart failure due to myocardial infarction and aging. Heart Fail Rev. 2011; doi: 10.1007/s10741-011-9278-7.
7. Morano I, Hadicke K, Haase H, et al. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol. 1997; 29: 1177-87.
8. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res. 1998; 39: 60-76.
9. 2+-handling proteins and heart failure: novel molecular targets? Curr Med Chem. 2003; 10: 967-81.
10. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, et al. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res. 2009; 81: 429-38.
11. Machackova J, Barta J, Dhalla NS. Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies. Can J Cardiol. 2006; 22: 953-68.
12. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1995; 12: 205S-13S.
13. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma-renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(Suppl. VI): 40-8.
14. Esler M, Lambert G, Brunner-La Rocca HP, et al. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand. 2003; 177: 275-84.
15. Sallach JA, Goldstein S. Use of beta-blockers in congestive heart failure. Ann Med. 2003; 35: 259-66.
16. Krum H. Beta-blockers in heart failure. The 'new wave' of clinical trials. Drugs. 1999; 58: 203-10.
17. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360: 752-60.
18. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362: 777-81.
19. Guo X, Saini HK, Wang J, et al. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of renin angiotensin system. Expert Rev Cardiovasc Therap. 2005; 3: 717-32.
20. 2+ transport in heart failure due to myocardial infarction. J Mol Cell Cardiol. 1999; 31: 1663-72.
21. 2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol. 2005; 288: H2637-46.
22. 2+-transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol. 2005; 288: H1674-82.
23. +-pump capacity in congestive heart failure following myocardial infarction in rats. J Mol Cell Cardiol. 1998; 30: 1311-28.
24. Hanatani A, Yoshiyama M, Takeuchi K, et al. Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats. Jpn J Pharmacol. 1998; 78: 45-54.
25. Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol Cell Biochem. 2003; 254: 163-72.
26. Wang J, Guo X, Dhalla NS. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta. 2004; 1690: 177-84.
27. Wang J, Liu X, Ren B, et al. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol. 2002; 34: 847-57.
28. 2+ handling in the post-infarction rat heart. Cardiovasc Res. 2008; 79: 42-51.
29. Sun YL, Hu SJ, Wang LH, et al. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest. 2005; 128: 1812-21.
30. Omerovic E, Bollano E, Soussi B, et al. Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. Eur J Heart Fail. 2003; 5: 725-32.
31. Omerovic E, Bollano E, Mobini R, et al. Selective beta(1)-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling. Biochem Biophys Res Commun. 2001; 281: 491-8.
32. Dhalla NS, Dent MR, Tappia PS, et al. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Therapeut. 2006; 11: 31-45.
33. Gurevich AK, Falk SA, Nemenoff RA, et al. Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction. Drugs R D. 2002; 3: 239-49.
34. Machackova J, Sanganalmath SK, Barta J, et al. Amelioration of cardiac remodelling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity. Cardiovasc Toxicol. 2009; 10: 9-16.
35. Machackova J, Sanganalmath SK, Elimban V, et al. β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med. 2011; 15: 545-54.
36. Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res. 1990; 66: 782-8.
37. Dixon IM, Hata T, Dhalla NS. Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 1992; 31: H1387-94.
38. Sanganalmath SK, Barta J, Takeda N, et al. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol. 2008; 86: 180-9.
39. Sanganalmath SK, Babick AP, Barta J, et al. Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure. J Cell Mol Med. 2008; 12: 1728-38.
40. Wang J, Liu X, Sentex E, et al. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol. 2003; 284: H2277-87.
41. Sjaastad I, Sejersted OM, Ilebekk A, et al. Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol. 2000; 89: 1445-54.
42. Birkeland JA, Sjaastad I, Brattelid T, et al. Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Br J Pharmacol. 2007; 150: 143-52.
43. Huang BS, Ahmad M, Tan J, et al. Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post myocardial infarction. Am J Physiol Heart Circ Physiol. 2009; 297: H968-75.
44. Zhu YZ, Zhu YC, Li J, et al. Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. J Renin Angiotensin Aldosterone Syst. 2000; 1: 257-62.
45. Sethi R, Shao Q, Ren B, et al. Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. Mol Cell Biochem. 2004; 263: 11-20.
46. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol. 2001; 37: 1461-6.
47. Afzal N, Dhalla NS. Differential changes in left and right ventricular SR calcium transport in congestive heart failure. Am J Physiol Heart Circ Physiol. 1992; 262: H868-74.
48. Ren B, Shao Q, Ganguly PK, et al. Influence of long-term treatment of imidapril on mortality, cardiac function, and gene expression in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol. 2004; 82: 1118-27.
49. 1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res. 1997; 35: 223-32.
50. +-ATPase remodeling in failing rat heart due to myocardial infarction. Can J Physiol Pharmacol. 2008; 86: 139-47.
51. Saini HK, Shao Q, Musat S, et al. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol. 2005; 144: 202-11.